Enanta Pharmaceuticals to Appeal Ruling in Patent Infringement Case Against Pfizer

 Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents.

The U.S. District Court of Massachusetts ruled that Pfizer's motion that U.S. Patent Number 11,358,953 is invalid, Enanta said Tuesday.

Through a patent infringement lawsuit, the clinical-stage biotechnology was seeking damages for infringement of the patent in the manufacture, use and sale of Pfizer's Paxlovid.

The court also denied Enanta's partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity.

"Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit," it said.

https://www.marketscreener.com/quote/stock/PFIZER-INC-23365019/news/Enanta-Pharmaceuticals-to-Appeal-Ruling-in-Patent-Infringement-Case-Against-Pfizer-48650641/